| 9.08 0.2 (2.25%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 13.81  |
1-year : | 16.01 |
| Resists | First : | 11.82 |
Second : | 13.71 |
| Pivot price | 10.11 |
|||
| Supports | First : | 8.77 |
Second : | 7.3 |
| MAs | MA(5) : | 9.19 |
MA(20) : | 10.43 |
| MA(100) : | 10.64  |
MA(250) : | 13.34 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 4.3 |
D(3) : | 3.4 |
| RSI | RSI(14): 32.4 |
|||
| 52-week | High : | 22.93 | Low : | 6.57 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ETNB ] has closed above bottom band by 13.7%. Bollinger Bands are 4.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.12 - 9.18 | 9.18 - 9.24 |
| Low: | 8.63 - 8.71 | 8.71 - 8.78 |
| Close: | 8.96 - 9.08 | 9.08 - 9.19 |
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
Thu, 11 Apr 2024
89bio (NASDAQ:ETNB) Stock Price Down 4.2% - MarketBeat
Wed, 03 Apr 2024
89bio Inc CEO Rohan Palekar Sells 52,718 Shares - Yahoo Finance
Wed, 20 Mar 2024
Can 89bio Inc (ETNB) Stock Rise to the Top of Healthcare Sector Wednesday? - InvestorsObserver
Thu, 07 Mar 2024
Over $20M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying - Markets Insider
Tue, 05 Mar 2024
89BIO (ETNB) Just Overtook the 200-Day Moving Average - Yahoo Finance
Sun, 03 Mar 2024
89Bio Inc Is Worried About This – Should You Be Worried Too? - TipRanks.com - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 94 (M) |
| Shares Float | 70 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 106.2 (%) |
| Shares Short | 11,550 (K) |
| Shares Short P.Month | 10,860 (K) |
| EPS | -2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.75 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -23.9 % |
| Return on Equity (ttm) | -41.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.62 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -129 (M) |
| Levered Free Cash Flow | -83 (M) |
| PE Ratio | -4.54 |
| PEG Ratio | -0.5 |
| Price to Book value | 1.57 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.58 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|